Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY: GKOS )

153.20 +6.82 (+4.66%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 747,257
Open 146.97
Bid (Size) 148.14 (1)
Ask (Size) 162.86 (1)
Prev. Close 146.38
Today's Range 146.82 - 154.06
52wk Range 83.90 - 163.71
Shares Outstanding 55,137,429
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Glaukos's Recent Short Interest
Via Benzinga
How Is The Market Feeling About Glaukos?
Via Benzinga

Performance

YTD
+2.35%
+2.35%
1 Month
-2.11%
-2.11%
3 Month
+11.84%
+11.84%
6 Month
+21.11%
+21.11%
1 Year
+65.39%
+65.39%

More News

Read More
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
From Glaukos Corporation
Via Business Wire
What 11 Analyst Ratings Have To Say About Glaukos
Via Benzinga
(GKOS) - Analyzing Glaukos's Short Interest
Via Benzinga
How Is The Market Feeling About Glaukos?
Via Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
Via Benzinga
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
Via Benzinga
Topics Fraud
Exposures Legal
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Via Benzinga
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
How Is The Market Feeling About Glaukos?
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Glaukos
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
Via Talk Markets
Topics Stocks / Equities
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Via Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Via Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
From Glaukos Corporation
Via Business Wire
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.